<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/BioNTech-SE-ADR-US09075V1026">BioNTech SE - ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/05/3287464/0/en/BioNTech-Announces-First-Quarter-2026-Financial-Results-and-Corporate-Update.html">BioNTech Announces First Quarter 2026 Financial Results and Corporate Update</a>
    </div>

      <div class="me-0 me-md-5">
        BioNTech SE (Nasdaq: BNTX) today reported financial results for the three months ended March 31, 2026 and provided an update on its corporate progress.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/BioNTech-SE-ADR-US09075V1026">BioNTech SE - ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/health/healthcare/new-drugs-for-pancreatic-cancer-show-remarkable-promise-for-deadly-disease-b4e1b504">Two experimental drugs showed striking early results against pancreatic cancer</a>
    </div>

      <div class="me-0 me-md-5">
        Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/BioNTech-SE-ADR-US09075V1026">BioNTech SE - ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/21/3277750/0/en/BioNTech-to-Report-First-Quarter-2026-Financial-Results-and-Corporate-Update-on-May-5-2026.html">BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026</a>
    </div>

      <div class="me-0 me-md-5">
        MAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and p...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/BioNTech-SE-ADR-US09075V1026">BioNTech SE - ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/investing/2026/04/15/2-healthcare-stocks-to-buy-and-1-to-approach-with/">2 Healthcare Stocks to Buy and 1 to Approach With Caution</a>
    </div>

      <div class="me-0 me-md-5">
        Zoetis has strong growth prospects and an attractive income program. BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/BioNTech-SE-ADR-US09075V1026">BioNTech SE - ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/11/3272109/0/en/BioNTech-and-DualityBio-s-Antibody-Drug-Conjugate-Trastuzumab-Pamirtecan-Demonstrated-Clinically-Meaningful-Efficacy-in-Patients-with-HER2-Expressing-Recurrent-Endometrial-Cancer.html">BioNTech and DualityBio&#39;s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer</a>
    </div>

      <div class="me-0 me-md-5">
        BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/BioNTech-SE-ADR-US09075V1026">BioNTech SE - ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-biontech-halt-us-covid-vaccine-study-after-recruitment-struggles-2026-04-01/">Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles</a>
    </div>

      <div class="me-0 me-md-5">
        Vaccine makers Pfizer ‌and BioNTech have halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment ​in the trials had been too low to generate ​the needed data.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/BioNTech-SE-ADR-US09075V1026">BioNTech SE - ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">24/7 Wall Street</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://247wallst.com/investing/2026/03/30/3-companies-built-their-fortunes-on-covid-vaccines-but-only-1-has-a-real-plan-for-what-comes-next/?utm_source=snapi">3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next</a>
    </div>

      <div class="me-0 me-md-5">
        The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/BioNTech-SE-ADR-US09075V1026">BioNTech SE - ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/24/3261033/0/en/BioNTech-Clinical-Data-at-ELCC-2026-Highlight-Potential-of-Differentiated-Late-Stage-Portfolio-in-Lung-Cancer.html">BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer</a>
    </div>

      <div class="me-0 me-md-5">
        MAINZ, Germany, March 24, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data from its diversified portfolio in the field of lung cancer at the European Lung Cancer Congress (“ELCC”) held in Copenhagen, Denmark, from March 25-28, 2026. The data updates covered in both oral and poster presentations highlight progress across late-stage immunomodulator candidates pumit...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/BioNTech-SE-ADR-US09075V1026/load_more?page=5">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>